The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.
 
Mark Voskoboynik
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Gary Edward Richardson
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Merck (Inst); Novotech (Inst); Pfizer (Inst); Roche/Genentech (Inst); Shanghai Henlius Biotech (Inst); Suzhou Alphamab (Inst); Takeda (Inst)
 
Linda R. Mileshkin
No Relationships to Disclose
 
Catriona M. McNeil
Research Funding - MSD Oncology (Inst)
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Consulting or Advisory Role - Imagion Biosystems
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag; Pfizer
 
Fabio M. Benedetti
Employment - Apollomics; Taiho Oncology
Leadership - Apollomics; Taiho Pharmaceutical
Stock and Other Ownership Interests - Abbvie; Acadia; Affimed Therapeutics; Aimmune; Alnylam; Amarin Corporation; Amgen; Apollomics; ArQule; Array BioPharma; Asterias Biotherapeutics; AstraZeneca; Atara Biotherapeutics; Bellicum Pharmaceuticals; Bluebird Bio; Blueprint Medicines; Bristol-Myers Squibb; Cascadian Therapeutics; catabasis; celgene; Cellectis; celyad; crispr therapeutics; Editas Medicine; epizyme; Exelixis; Fate Therapeutics; Forty Seven; Geron; Gilead Sciences; Ignyta; Immunogen; Immunomedics; incyte; Infinity Pharmaceuticals; Intellia Therapeutics; ION Pharma; Johnson & Johnson; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Lexicon; Lilly; loxo; Macrogenics; Medtronic; MEI Pharma; Merck; Neurocrine Biosciences; Newlink Genetics; pfizer; Puma Biotechnology; Regenxbio; Seagen; Spring Bank; Stemline Therapeutics; Syndax; tocagen; Ultragenyx Pharmaceuticals; uniqure; verastem
Patents, Royalties, Other Intellectual Property - 2 patent applications under same Title: Method for treating cancer patients with c-Met point mutation or c-Met fusion gene; 2 patent applications under same Title: Method for treating cancer patients with c-Met point mutation or c-Met fusion gene; A patent relating to telomere length as a predictor for thrombocytopenia for patients treated with GRN163L (a Geron experimental therapeutic)
 
Gavin S. Choy
Employment - Apollomics
Leadership - Apollomics
Stock and Other Ownership Interests - Apollomics
Research Funding - Apollomics
Travel, Accommodations, Expenses - Apollomics
 
Neil Sankar
No Relationships to Disclose
 
Shelly McCurry
No Relationships to Disclose
 
Xiaoling Zhang
Employment - Apollomics; AstraZeneca
Stock and Other Ownership Interests - Agios; Apollomics; Bristol-Myers Squibb; Clovis Oncology; Dynavax Technologies; Exelixis; Fate Therapeutics; FibroGen; ImmunoGen; Immunomedics; Karyopharm Therapeutics
 
Min Gao
Employment - Apollomics; Astex Pharmaceuticals (I)
 
Ajit K. Shah
Consulting or Advisory Role - Apollomics
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MaxiNovel (Inst); Novartis (Inst); PIN Pharma (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche